Analysis finds that sensor provides timely and actionable patient interventions, reducing the necessity for emergency interventions and potential hospital transfers.
Toronto, ON – 15 July 2024 – Xandar Kardian Inc, known for its revolutionary approach to monitoring vital signs using ultra-wide band radar, announced today that is has achieved validation for health outcomes from Validation Institute for its XK300 sensor.
The XK300 sensor was the first commercially available, US FDA 510(K) cleared, Class II medical device to use radar to monitor vital signs. By combining sophisticated radar technology capable of detecting micro and nano vibrations emitted from the human body, with proprietary digital signal processing algorithms, the XK300 enables continuous, autonomous and contact-free monitoring of vital signs under various conditions and through obstructions like blankets and clothing.
The Institute validated the claim that Xandar Kardian’s XK300 sensor and its Probability Baseline Change Score (POBC) are effective for the early detection of clinical changes to enable early intervention. “Xandar Kardian’s contactless health monitoring system XK300 uses continuous heart and respiratory data together to predict that a person is likely to have a hospital transfer. The system, combined with POBC score predicted 75.6% of hospital transfers in the study group,” said Craig Sharpe, Chief Operating Officer, Validation Institute. “The sensor has improved health outcomes, and as a result, we are proud to award this validation to Xandar Kardian,” Mr. Sharpe continued.
“By notifying the care provider when vital signs change in a meaningful way, providers can intervene sooner, prioritize care, and triage patients who need closer assessment,” said Linda Mayhue, Senior Director, Clinical and Customer Success, at Xandar Kardian. “Validation Institute’s independent analysis is yet another example of the measurable impact of the XK300 sensor and its potential to improve health outcomes in near real-time,” Ms. Mayhue went on to state.
Proprietary algorithms driven by the XK300 are designed to provide timely and actionable patient interventions, reducing the necessity for emergency interventions and potential hospital transfers. The validation report is available for download at: https://validationinstitute.com/validated-provider/xandar-kardian. Additional information on the XK300 can be found at: https://xkcorp.com/products/health-care/xk-300.
About Validation Institute
Validation Institute provides unbiased, data-driven insights on healthcare solutions and services by validating performance claims made by solution providers and educating purchasers to drive transparency in the marketplace and maximize cost-savings. More information is available at
https://www.ValidationInstitute.com
About Xandar Kardian
Xandar Kardian is a US Delaware C-Corp, headquartered in Canada with international operations in Asia and North America, focused on deploying reliable and high accuracy healthcare and built environment solutions worldwide. Xandar Kardian elevates motion sensor technology to the next level, incorporating radar sensors that monitor vital signs via resting heart rate (RHR) and respiratory rate (RR), providing essential insights into occupant motion, location, and vital sign reading. Founded in 2017, the team behind Xandar Kardian is focused on digital radar signal processing from start-to-finish, building on their FDA 510(k) Clearance for its XK300 and ability to measure vitals and presence from up to 33 feet away from the patient. For more information, please visit https://xkcorp.com.
Login with Google